All biopharmaceuticals articles
-
ArticlePrecision control for target protein degraders
Target protein degraders offer therapeutic potential, yet their high potency, poor solubility and ultra-low administered doses place significant demands on formulation science, analytical capability, containment and scalable manufacture. Successful development requires solubility enhancement, particle engineering, excipient design, high-potency containment and process development to be considered together from the earliest programme stages.
-
ArticleClosing the data integrity gap in pharmaceutical quality control
Pharmaceutical quality control laboratories face growing pressure to strengthen data integrity as regulators scrutinise incomplete records, manual data entry, and disconnected systems.
-
WebinarFrom passive to active air monitoring in aseptic filling: a risk-based approach to replacing settle plates
In this webinar, Particle Measuring Systems will share a case study of a biopharmaceutical company developing and applying a structured global rationale for the implementation of continuous viable environmental monitoring with a single-use microbial impactor within aseptic manufacturing environments.
-
ArticleLab 4.0 balance: connected, compliant and ready to integrate
Combining connectivity, compliance and automation, Lab 4.0 connectivity simplifies workflows, reduces manual intervention and supports secure digital transformation in modern pharmaceutical laboratories.
-
ArticleSandoz expands biosimilar pipeline through $322m Henlius deal
Sandoz has entered a collaboration with Shanghai Henlius Biotech to develop and commercialise up to 10 biosimilars in a deal worth up to $322 million, expanding its pipeline with assets referencing established therapies including Erbitux, Repatha and Benlysta.
-
NewsBiopharmaceutical PAT market forecast to reach $4.32bn
Growing demand for real-time process monitoring and more consistent biopharmaceutical manufacturing is expected to drive investment in process analytical technology.
-
NewsBioNTech appoints Guido Oelkers as new Chief Executive Officer
German biotech’s incoming leader set ahead of its goal of having multiple approved products by 2030.
-
NewsR&D and tech innovation boosting biopharmaceutical market to 2030
Advanced technology innovation is driving lower R&D costs and progress of targeted treatments such as cell and gene therapies, the research reports.
-
NewsNew mass spectrometry Chapter could “revolutionise” biopharma quality assurance
Launch of the USP general method chapter signals a breakthrough in pharmaceutical drug impurity control, according to biopharma experts.